birtamimab
Monoclonal antibody
Evidence outlook · program status
Discontinued (2025-05), after a negative readout
Phase 3 AFFIRM-AL (NCT04973137) missed its primary endpoint (announced 2025-05-23); Prothena stopped all development. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01707264 NCT01707264 · AL Amyloidosis Registry: NCT01707264 | 1/2 | Safety and tolerability (28 day cycles, up to 1 year; beyond 1 year with approval of Sponsor and Investigator); Maximum tolerated dose (28 day cycles, up to 1 year; beyond 1 year with approval of Sponsor and Investigator) 2016-08-09 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 2 more trials
AFFIRM-AL NCT04973137 · AL Amyloidosis Registry: NCT04973137 | 3 | Time to All-cause Mortality for the Double Blind Phase (Time from the first dose of study drug until the pre-defined number of events (all-cause mortality) have been reached, assessed up to 39 months.) 2025-04-02 | Stopped early (terminated). Key figures are not recorded here. | not yet graded | link ↗ |
VITAL NCT02312206 · AL Amyloidosis Registry: NCT02312206 | 3 | Time to Composite of All-cause Mortality or Cardiac Hospitalization (Randomization until the date of death or cardiac hospitalization, up to 32 months) 2018-05 | Stopped early (terminated). Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for AL Amyloidosis: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Birtamimab: this drug | Discontinued | Monoclonal antibody | Misfolded immunoglobulin light chain (AL amyloid) | not yet graded | No reviewed efficacy summary in this indication | |
| Anselamimab (Amlypave) | Phase 3 | Monoclonal antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Daratumumab | Phase 3 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| Etentamig | Phase 3 | Multispecific antibody | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| SCTC21C | Phase 3 | Biologic (subtype unspecified) | CD38 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent